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V. Abstract
Increased Alzheimer’s disease (AD) risk has previously been associated with a
SNP called rs610932 near the gene MS4A6A. The goal of this experiment was to quantify
the expression of two MS4A6A isoforms in the brains of AD and non-AD subjects,
particularly as a function of rs610932 genotype. According to an article titled
“Alzheimer’s Disease Susceptibility Variants in the MS4A6A Gene are Associated with
Altered Levels of MS4A6A Expression in Blood”, MS4A6A has four different isoforms
that have been reported to be differentially expressed in the blood of AD subjects
compared to non-AD subjects (Petroula et al., 2014). After statistically analyzing the
association between two of the MS4A6A variants, Isoform 6 (total MS4A6A transcript)
and a variant, Isoform 4, and rs610932 using AD status and microglial expression as
independent variables, we found significant expression differences in AD and non-AD
subjects in the brain for the Isoform 4. We did not detect significant expression
differences for Isoform 6 in AD subjects, nor did we find significant expression
differences in either isoform as a function of the rs610932 SNP. These results are in
contrast to previous findings that suggested a significant expression difference due to
rs610932 in whole blood (Petroula et al., 2014). In summary, further work is necessary to
understand how rs610932 modulates MS4A6A to alter AD risk.

VI. Introduction
Nearly 70% of the risk of late onset Alzheimer’s disease (AD) is heritable. AD
risk has been linked with genetic variants in different genes. This disease is a form of
dementia that affects memory, thinking and behavior. AD tends to start slowly, but then

develops over time. The largest risk factor to acquire AD is age and there is no current
cure for the disease. Symptoms that correspond to AD include memory loss, confusion,
mood changes, and poor judgment (Malik et al. 2015)
There are two main neuropathologic findings that correlate with AD. The first is
when a type of plaque builds between the neurons of the brain (Sakae et al. 2016). These
plaques are made of beta-amyloid protein, and they usually arise in the memory area of
the brain (Sakae et al. 2016). The second finding is the formation of neurofibrillary
tangles (Baker and Gotz 2016). These tangles are composed of a protein called tau that
builds up inside of the neurons (Baker and Gotz 2016). Plaques and tangles are believed
to block nerve cell communication, eventually leading to cell death (Baker and Gotz
2016).
The root cause of AD is not fully known, but large-scale genetic studies have
identified a set of SNPs that are associated with AD risk. These SNPs have suggested that
AD is the result of an immune system defect. One gene in particular that has recently
emerged as a candidate for contributing to AD is MS4A6A (Deng et al., 2012). This gene
is part of the MS4A gene family, which consists of 12 related genes. The gene is found on
chromosome 11q12.1. Although there are 12 members of the MS4A gene family, MS4A1,
MS4A2, and MS4A3 are the most well known genes (Petroula et al., 2014).
MS4A6A encodes a member of the membrane-spanning 4A (MS4A) gene family,
and typically consists of six exons. The proteins produced from this gene are often
alternatively spliced, and there are four known isoform transcripts that are translated. A
schematic representation of two MS4A6A variants analyzed in this study is shown in
Figure 1 (Petroula et al., 2014). MS4A6A is 13,060 base pairs in length and encodes a

total of 248 amino acids in the transcript’s full form. The different isoforms produced
from this gene are the result of variations in splicing and, possibly, single nucleotide
polymorphisms (SNPs). The SNP of interest is rs610931. This SNP causes a thymine (T)
to be changed to a guanine (G), and is located at the end of the MS4A6A gene (Petroula
et al., 2014). G is the major allele and T is the minor, protective allele. This SNP has been
associated with altered MS4A6A expression in whole blood samples (Petroula et al.,
2014).
This particular gene, along with its four variant transcripts, is hypothesized to
contribute to AD susceptibility. There is evidence that subjects with Alzheimer’s disease
have an increased expression of the MS4A6A transcript in the blood (Petroula et al.,
2014). The goal of this experiment was to link two of the MS4A6A variants’ gene
expression in the brain, Isoform 6 and Isoform 4 (V1 and V4 in Figure 1), with
Alzheimer’s disease, particularly as a result of rs610932.

VII. Methods
The conductance of all experiments were in compliance with specific, applicable
Chemical Hygiene, Radiation Safety, Institutional Biological Safety, and Institutional
Review Board protocols.

Subjects:
The University of Kentucky Alzheimer’s Disease Center Neuropathology Core
provided all human brain specimens. The specimens came from the anterior cingulate.
Figure 2 shows a diagram of where the anterior cingulate is located in the brain
(Thompson 2013). Diagnosing the AD and non-AD subjects was done at a conference of
the AD Center Neuropathology and Clinical Cores. Diagnosis was based on evaluation of
cognitive status and neuropathology. Cognitive status was determined using tests such as
Clinical Dementia Rating and Mental State Examination (MMSE) scores (Grear et al.,
2009). Neuropathology was determined based on tests such as Braak stages and NIAReagan Institute (NIA-RI) neuropathological classification (Grear et al., 2009). NIA-RI
includes counts of both neurofibrillary tangles and neuritic senile plaques, and provides
staging for AD diagnosis. Individuals that were diagnosed non-AD had an age of death of
82 ± 9 years (mean ± SD, n = 28). Those diagnosed as AD had an age of death of 82 ± 6
years (n=29). In non-AD patients, the average post mortem interval (PMI) was 2.8 ± 0.8
hours (mean ± SD, n = 28), while AD individuals had a PMI of 3.4 ± 0.6 hours (n = 29).
Mini-Mental State Examination (MMSE) scores for non-AD individuals were 28.4 ±1.6
(n = 28). The temporal lobe samples were prepared in order to compare MS4A6A
expression between white and gray matter. White and gray matter was removed from the
temporal lobe, and the quality of these specimens was confirmed by comparing the ratio
of mRNAs associated with different cell types (Grear et al., 2009).

Genotyping:
The first method used in this study was to genotype the genomic DNA samples
with a SNP kit that corresponds to the rs610932 SNP found in the MS4A6A gene. The
TaqMan® SNP Genotyping Assays were ordered from Applied Biosystems (Foster City,
California, USA). They were centrifuged and diluted with 564 μL of water. A master mix
was then made using 700 μL of TaqMan® Genotyping Master Mix, 70 μL of the diluted
SNP Kit, and 560 μL of water. The TaqMan® Genotyping MM was also ordered from
Applied Biosystems. Nineteen μL of the master mix was pipetted into target wells,
followed by 1 μL of DNA from the samples. Negative controls that had no DNA were
also used. The pipettes used in this experiment (Pipetmen, Gilson Inc., Middleton,
Wisconsin, USA) were used with ZAP Premier sterile aerosol pipet tips (Labcon Inc.,
Petaluma, CA, USA) to eliminate aerosol carryover between samples. Once the wells had
all 20 μL of liquid, the 96-well plate was placed in an MJ Research Peltier Thermal
Cycler (PTC-200, MJ Reseach, Bio-Rad Inc., Hercules, CA, USA). The plate was
incubated at 95° C for 10 minutes, 95° C for 15 seconds, and 60° C for 1 minute. Steps 2
and 3 were repeated for 39 more minutes. Once the 96-well plate was incubated, the
results were analyzed through MJ Opticon Monitor Analysis Software (version 3.1; BioRad Inc.). The graph showing the genotyping results is shown in Figure 3.

Test PCR Primers:
Primers for MS4A6A were ordered (Invitrogen Inc., Carlsbad, CA, USA) for
exons 1, 2, 4, 5, and 6. The primers were first dissolved with water to generate a stock
concentration of 50 μM. Once done, a master mix was made using the following: 30 μL

of 10X PCR reaction buffer, 9 μL of 50 mM magnesium chloride (New England BioLabs
Inc., Ipswich, MA, USA), 1.2 μL of 25 mM dNTP’s, 2.04 μL of Taq Polymerase
(Invitrogen), and 233.76 μL of water. Once the master mix was made, 26 μL was pipetted
into five Eppendorf tubes. The diluted primers were then added to the five tubes. Six μL
of primer pair 1 was added to the first tube; 6 μL of primer pair 2 was added to the
second tube, and this proceeded for all five primer pairs. Twenty-four μL was pipetted
from each of the five tubes into different wells in a 96-well PCR plate. Two rows of five
wells each were used. Once the ten wells were filled with 24 μL of solution, 1 μL of
cDNA was added to each well. The cDNA was selected based on the genotyping results.
There were five samples that were homozygous for VIC®, and five samples that were
homozygous for carboxyfluorescein (FAM). Vic® (minor allele) and FAM (major allele)
are fluorescent dyes. Lastly, the 96-well plate was placed into a Veriti 96 Well Thermal
Cylcer (Applied Biosystems Corp., Foster City, CA, USA). The samples were run for 30
cycles at 94° C for 2 minutes, 94° C for 15 seconds, 60° C for 15 seconds, 72° C for 30
seconds, 72° C for 7 minutes, and then cooled to 25° C. Steps 2, 3 and 4 were run for 30
cycles.
Once the PCR was complete, the amplified DNA was separated through gel
electrophoresis. A 20 cm X 20 cm 10% polyacrylamide gel was made using the following
ingredients: 7.5 mL of 30% Acrylamide (29:1), 11.7 mL of water, 6 mL of 5X TrisBorate-EDTA (TBE), 4.6 mL of 50% glycerol, 0.3 mL of 10% Ammonium Persulfate
(APS), and 0.02 mL of TEMED. The Acrylamide was ordered from Bio-Rad
Laboratories (Hercules, CA, USA), and the TEMED was ordered from Calbiochem®
(San Diego, CA, USA). The gel was allowed to set and was then placed on a Vertical Gel

Electrophoresis System made by Bethesda Research Laboratories (BRL; Thermofisher,
Grand Island, NY, USA). A buffer was prepared using 400 mL of 5X TBE and 1600 mL
of water. The buffer was then poured into the top and bottom of the electrophoresis
system. Five μL of loading dye was placed into each of the wells on the PCR well-plate.
A syringe (Hamilton Co., Reno, NV, USA) was used to pipet 10 μL of a 1 Kb+ ladder
(ThermoFisher, Grand Island, NY, USA) into the first well, followed by 15 μL in each of
the other wells. The samples were then run on the gel using 200 volts from a Fisher
Biotech Electrophoresis Systems amplifier until the DNA was far enough down the gel
for distinct band resolution. Once the samples migrated far enough, the gel was removed
and placed into a solution containing 5X TBE buffer and SYBR® Gold stain (Molecular
Probes Inc., Eugene, Oregon, USA). SYBR® Gold is a nucleic acid gel stain. The gel
was placed on a shaker for 15 minutes and then placed on a Fujifilm FLA-2000
transilluminator to view the bands made by the DNA. The software used to start, view,
and manipulate the gel was Image Reader FLA-2000 (version 1.8) and Multi Gauge
(version 3.0).
After testing the primers and viewing the corresponding gel, another PCR reaction
was run. Five samples of homozygous VIC and 5 samples of homozygous FAM cDNA
were used in the PCR reaction. The PCR product was then run on a 10% polyacrylamide
gel, following the same procedure as before. All other primers were also used to amplify
their respective amplicons using PCR and run on the gel. After viewing the gel in the
FLA-2000, amplicons were cut for primer set 6 and primer set 4 reactions. Primer set 6
(6F-6R) amplifies an MS4A6A fragment found in all transcripts, while primer set 4 (4F4R) amplifies a fragment that contains a retained intron 2. (Figure 1).

Purifying PCR Product
Once the bands of DNA were excised from the gels, the gel fragments were
crushed and the DNA purified. DNA was purified from the gel using a QIAquick® PCR
Purification Kit (Qiagen Inc., Valencia, CA, USA). This process was carried out using
the protocol found for the QIAquick® PCR Purification Kit found on the Qiagen website.
After purification was complete, the samples were subjected to UV spectroscopy
to quantify the DNA concentration in solution. This was done using a NanoDrop 2000
UV-Vis Spectrophotometer. First, 1 μL of water was used as a blank in the machine.
Once the blank was read and the machine properly zeroed, 1 μL of the purified PCR
product was placed on the reading eye. Graphs were obtained for both the primer set 6
PCR product (all transcripts) and the primer set 4 (variant 4) PCR product (data not
shown).

Real-Time PCR
Quantitative real-time PCR, or qPCR, was used to monitor PCR reaction
efficiency and the absolute quantification of two MS4A6A isoforms, isoform 4 and
isoform 6 (whole transcript). A master mix containing 20 ng of the cDNA subjects, 10 μL
of SYBR green reagent (Quanta Biosciences, Gaithersburg, Maryland, USA), 10 μL of
water, and 10 μL of forward and reverse primers was used. Once the master mix is made,
it was pipetted into wells, and then placed into an MJ Opticon 4 thermal cycler (Biorad).
The samples were cycled under the following conditions: 95° for 3 minutes to denature,
followed by 40 cycles of a 95° C denaturation step for 15 seconds and a 60° C

annealing/extension step for 45 seconds. Finally, a melting curve was used to view the
amplification fidelity in combination with inspection of PCR products on an 8% TBEPAGE gel (Simmons et al. 2011).
Using the PCR products created from this process, a standard curve was produced
consisting of 10-fold serial dilutions that were amplified with the samples in each PCR
run. By looking at these standard curves, PCR reaction efficiency can be monitored, and
quantification of MS4A6A isoforms can occur. (Simmons et al. 2011).

Statistical Analysis
Among the cohort of different brain samples, one outlier was excluded from the
statistical analysis. This sample had normalized MS4A6A isoform 4 expression much
higher than the median. A linear regression analysis using SPSS software was used to
analyze the association between normalized MS4A6A isoform 4 and normalized isoform
6 (whole transcript) and rs610932 genotype, AD status and microglia gene expression.
Microglia gene expression, AD status and rs610932 were the independent variables.

VIII. Results and Discussion
In this experiment, we chose to look at two of the isoforms for the MS4A6A gene,
isoform 6 (whole transcript) and isoform 4 (short transcript). In the statistical analyses,
we chose to analyze the normalized expression of the two transcripts in association with
normalized microglia gene expression. Microglia gene expression was chosen due to the
previously found linkage between expression of microglia genes and the MS4A6A
transcripts (Zhang et al. 2014). The plots showing the relationship between MS4A6A

isoforms and microglial content in the samples are shown in Figure 4. In Figure 4 (A), we
analyzed MS4A6A Isoform 4 expression in association with microglia gene expression
and the rs610932 genotype. In Figure 4 (B), we analyzed Isoform 4 expression in
association with microglia gene expression and AD status. We did not find a significant
association (p < 0.05) between MS4A6A Isoform 4 expression and the rs610932 genotype
(p-value = .132, power = .411). We did, however, find significant associations between
Isoform 4 expression and microglia gene expression (p-value = 1.1X10-4, power = .986)
and AD status (p-value = .002, power = .892). Microglia gene expression and Isoform 4
expression were expected to be associated due to a prior report than MS4A6A was
expressed in microglia (Zhang et al. 2014).
Figure 4 (C-D) shows the analysis results for MS4A6A Isoform 6 (total MS4A6A
expression). In Figure 4 (C), we analyzed Isoform 6 expression in association with
microglia gene expression and the rs610932 genotype. In Figure 4 (D), we analyzed
Isoform 6 expression in association with microglia gene expression and AD status. We
found no significant association between MS4A6A Isoform 6 expression and the rs610932
genotype (p-value = .193, power = .339). We also found no significant association
between Isoform 6 expression and AD status (p-value = .154, power = .294). We did,
however, find significance between Isoform 6 expression and microglia gene expression,
much like Isoform 4 (p-value = 1.0X10-6, power = 1.00)
Our results show an increased expression of the short form of MS4A6A, Isoform
4, in subjects with AD. We did not, however, find a significant association between the
rs610932 SNP and either Isoform 4 or Isoform 6. The latter findings are in contrast to
recent findings that showed a SNP association in whole blood (Petroula et al., 2014). Our

findings also showed significant association between Isoform 4 and Isoform 6 expression
and microglial gene expression, which is consistent with recent studies (Zhang et al.
2014).
These results indicate that an increase in expression of the truncated MS4A6A
variant (Isoform 4), through some kind of genetic influence or other factors, is correlated
with an increase in Alzheimer’s Disease prevalence. To know exactly how an increased
expression of Isoform 4 alters AD likelihood is challenging. The effect size of the
MS4A6A Isoform 4, which is associated with AD, is small (Petroula et al., 2014). With
this in mind, Isoform 4’s impact in AD pathology risk could be represented by the
differential expression that we found. The altered gene expression in AD subjects may
also be a consequence of other factors. Further research is needed to evaluate the effects
of over-expression of Isoform 4 in AD subjects.
With these results, MS4A6A continues to be a promising subject in Alzheimer’s
research. Further research needs to be done to determine the true reason why the
rs610932 SNP is correlated with increased AD risk. In addition to investigating the short
form of MS4A6A’s role in AD pathology, more research needs to be done to analyze the
association between the other two MS4A6A variants and AD susceptibility.

X. Conclusions
At the beginning of this study, we hypothesized that an increase in expression of
MS4A6A Isoform 4 and Isoform 6 are correlated with an increased risk in Alzheimer’s
Disease, particularly as a result of rs610932. The results of this study indicate a
significant association between Isoform 4 expression and AD status. With these data in

hand, we can accept the experimental hypothesis that MS4A6A variant expression is
associated with AD for Isoform 4. Since Isoform 6 did not have a significant association
between expression and AD status, we fail to accept that experimental hypothesis. We
also fail to accept the experimental hypothesis that the rs610932 SNP caused a significant
association between MS4A6A isoform expression and AD susceptibility.
The MS4A6A gene is a growing subject for researchers in the Alzheimer’s field,
as it has increasing potential for answers. With more and more data on this gene being
produced, we are gaining more knowledge on how it can contribute to AD pathology and
the possible mechanisms it uses to do so.
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XI. Tables
Table 1
Differential expression of MS4A6A in blood of control, MCI, and AD subject groups
(Petroula et al. 2014)
MS4A6A
transcript
V1 MS4A6A

Cohort (n)
Discovery (n = 207)
Validation (n = 299)

V4 MS4A6A

Control − MCI
p Value β (SE)
1.88 ×
− 0.593 (
10 −6
0.12)
0.854
0.022 (0.12)

Combined group
(n = 506)
Discovery (n = 209)

0.002
0.107

− 0.264 (
0.09)
0.131 (0.08)

Validation (n = 309)

1.89 ×
10 −04
1.82 ×
10 −04

0.303 (
0.08)
0.213 (
0.06)

Combined group
(n = 518)

Control − AD
p Value β (SE)
0.244
0.122
(0.11)
0.248 (
0.012
0.10)
0.200 (
0.009
0.08)
1.36 ×
0.408 (
10 −6
0.08)
7.51 ×
0.360 (
10 −8
0.07)
9.08 ×
0.372 (
10 −13
0.05)

MCI − AD
p Value β (SE)
5.73 ×
0.463 (
10 −8
0.08)
0.225 (
0.055
0.12)
5.38 ×
0.465 (
10 −9
0.08)
2.76 ×
0.234 (
10 −5
0.06)
0.447
0.058
(0.08)
0.159 (
0.002
0.05)

Total and individual variant expression was determined using real-time polymerase chain reaction. The
discovery groups are subjects who had previously been analyzed by microarray, while the validation group
had not been previously analyzed by microarray. Linear regression analyses were altered for age at
baseline, sex, number of APOE ε4 alleles, RNA integrity number (RIN), and center. Β-coefficients display
the change in MS4A6A gene expression between the groups using the first group as baseline.
Key: AD= Alzheimer’s Disease, MCI= mild cognitive impairment, SE = standard error.

XII. Figures

Fig. 1. Schematic depiction of the MS4A6A gene designating different transcript variants, location of
primers, and different single nucleotide polymorphisms (SNPs) associated with the gene. V1 corresponds to
Isoform 6 (whole transcript) and V4 corresponds to Isoform 4 (short transcript) (Petroula et al. 2014).

Fig. 2. Schematic representation of the human brain with a clear indication of where the anterior cingulate
is located.

Fig. 3. Results of genotyping assays. The upper-left group represents samples that were homozygous for
the minor allele (T). The lower-right group represents samples that were homozygous for the major allele
(G). The middle group represents samples that were heterozygous for both alleles. The lower-left group
represents negative controls in which no cDNA was added. VIC and FAM were used to designate major
and minor alleles.
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Figure 4. Isoform 4 and Isoform 6 (full-length) MS4A6A expression in brain associated with rs610932
genotype and AD status. (A) Linear regression analysis of normalized MS4A6A Isoform 4 expression
revealed a significant model (adjusted R squared=.387) wherein Isoform 4 expression was associated with
normalized microglial gene expression between subjects but not rs610932 genotype. (B) Linear regression
analysis of normalized MS4A6A Isoform 4 expression revealed a significant model when Isoform 4
expression was associated with normalized microglial gene expression and AD status. (C) Linear
regression analysis of normalized MS4A6A Isoform 6 expression revealed a significant model (R squared=
.427) when the whole transcript was associated with normalized microglial gene expression between
subjects but not rs610932 genotype. (D) Linear regression analysis of normalized MS4A6A Isoform 6
expression revealed a significant model when the transcript was associated with normalized microglial gene
expression but not AD status.

XIII. References Cited

Baker, S., & Got, J. (2016, March). A Local Insult of Okadaic Acid in Wild-type Mice
Induces Tau Phosphorylation and Protein Aggregation in Anatomically Distinct
Brain Regions. Neuroscience of Disease, 4(32).

Deng, Y. L., Liu, L. H., Wang, Y., Tang, H. D., Ren, R. J., Xu, W., & Ma, J. F. (2012,
July). The prevalence of CD33 and MS4A6A variant in Chinese Han population
with Alzheimer's disease. Human Genetics, 131(7), 1245-1249.

Grear, K. E., Ling, I. F., Simpson, J. F., Furman, J. L., Simmons, C. R., Peterson, S. L., &
Schmitt, F. A. (2009, November 4). Expression of SORL1 and a novel SORL1
splice variant in normal and Alzheimers disease brain. Molecular
Neurodegeneration, 4(46). doi: 10.1186/1750-1326-4-46

Malik, Manasi, Ishita Parikh, Jared B. Vasquez, Conor Smith, and Leon Tai. "Genetics
ignite focus on microglial inflammation in Alzheimer’s disease." Molecular
Neurodegeneration, vol. 10, no. 52, 2015.

(n.d.). In GeneCards-Human Gene Databse. Retrieved April 6, 2016, from

http://www.genecards.org

Petroula, P., Lee, S., Lunnon, K., Keohane, A., Powell, J., Troakes, C., & Al-Sarraj, S.
(2013, August). Alzheimer’s disease susceptibility variants in the MS4A6A gene
are associated with altered levels of MS4A6A expression in blood. Neurobiology
of Aging, 35(2014), 279-290.

Sakae, N., Liu, C., Shinohara, M., Frisch-Daiello, J., Ma, L., Yamazaki, Y., & Tachibana,
M. (2016, March 30). ABCA7 Deficiency Accelerates Amyloid-β Generation and
Alzheimer's Neuronal Pathology. The Journal of Neuroscience, 36(13), 38483859. Retrieved from PubMed.

Simmons, C. R., Zou, F., Younkin, S. G., & Estes, S. (2011, August 25). Evaluation of
the global association between cholesterol-associated polymorphisms and
Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in
disease risk. Molecular Degeneration, 6(62). doi:10.1186/1750-1326-6-62

Thompson, E. (2013, April 6). How to Transform Your Brain, Starting Right Now. In
Iawake Technologies. Retrieved April 6, 2016, from
http://www.iawaketechnologies.com/how-to-transform-your-brain-starting-rightnow/

Zhang, Ye, Kenian Chen, Steven A. Sloan, Mariko L. Bennett, and Anja R. Scholze. "An
RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and
Vascular Cells of the Cerebral Cortex." The Journal of Neuroscience, vol. 34, no.
36, 2014, pp. 11929-47. Accessed 1 Dec. 2016.

